Hepatitis Monthly

Published by: Kowsar

Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review

Seyed Moayed Alavian 1 , * and Hossein Haghbin 1
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: March 01, 2016, 16 (3); e35106
  • Published Online: March 6, 2016
  • Article Type: Review Article
  • Received: November 28, 2015
  • Revised: January 10, 2016
  • Accepted: January 27, 2016
  • DOI: 10.5812/hepatmon.35106

To Cite: Alavian S M, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review, Hepat Mon. 2016 ; 16(3):e35106. doi: 10.5812/hepatmon.35106.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015; 65(2): 87-108[DOI]
  • 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118(12): 3030-44[DOI][PubMed]
  • 4. McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15(2): 223-43[DOI][PubMed]
  • 5. Qureshi H. Aflatoxins and hepatitis b, c viral associated hepatocarcinogenesis. J Cell Sci. 2014; 5(5)[DOI]
  • 6. Sun Z, Chen T, Thorgeirsson SS, Zhan Q, Chen J, Park JH, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013; 34(8): 1800-5[DOI]
  • 7. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1): 51-68[PubMed]
  • 8. Follett EAC, Dow BC, McOmish F, Lee Yap P, Crawford RJ, Mitchell R, et al. HCV confirmatory testing of blood donors. The Lancet. 1992; 339(8798): 928-9[DOI]
  • 9. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl)-57[DOI][PubMed]
  • 10. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4): 264-9[PubMed]
  • 11. Booth JC, O'Grady J, Neuberger J, Thr Royal College of Physicians of London , The British Society of Gastroenterology . Clinical guidelines on the management of hepatitis C. Gut. 2001; 49 Suppl 1-21[PubMed]
  • 12. Viral hepatitis among Somali immigrants in Minnesota: association of hepatitis C with hepatocellular carcinoma. Mayo Clinic Proceedings : 17-24
  • 13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9): 603-5[DOI][PubMed]
  • 14. Bahri O, Ezzikouri S, Alaya-Bouafif NB, Iguer F, Feydi AE, Mestiri H, et al. First multicenter study for risk factors for hepatocellular carcinoma development in North Africa. World J Hepatol. 2011; 3(1): 24-30[DOI][PubMed]
  • 15. Shaker MK, Abdella HM, Khalifa MO, El Dorry AK. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 Cases. Liver International. 2013; 33(10): 1601-6[DOI]
  • 16. Schiefelbein E, Zekri AR, Newton DW, Soliman GA, Banerjee M, Hung Ch W, et al. Hepatitis C virus and other risk factors in hepatocellular carcinoma. Acta Virol. 2012; 56(3): 235-40[PubMed]
  • 17. Abdel-Wahab M, El-Ghawalby N, Mostafa M, Sultan A, El-Sadany M, Fathy O, et al. Epidemiology of hepatocellular carcinoma in lower Egypt, Mansoura Gastroenterology Center. Hepato-gastroenterology. 2006; 54(73): 157-62
  • 18. Ezzat S, Abdel-Hamid M, Eissa SA, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health. 2005; 208(5): 329-39[PubMed]
  • 19. El-Zayadi AR, Badran HM, Barakat EM, Attia Mel D, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005; 11(33): 5193-8[PubMed]
  • 20. El-Kafrawy SA, Abdel-Hamid M, El-Daly M, Nada O, Ismail A, Ezzat S, et al. P53 mutations in hepatocellular carcinoma patients in Egypt. Int J Hyg Environ Health. 2005; 208(4): 263-70[DOI][PubMed]
  • 21. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol. 2001; 33(2): 123-6[PubMed]
  • 22. Mabrouk GM. Prevalence of hepatitis C infection and schistosomiasis in Egyptian patients with hepatocellular carcinoma. Dis Markers. 1997; 13(3): 177-82[PubMed]
  • 23. Darwish MA, Issa SA, Aziz AM, Darwish NM, Soliman AH. Hepatitis C and B viruses, and their association with hepatocellular carcinoma in Egypt. J Egypt Public Health Assoc. 1992; 68(1-2): 1-9
  • 24. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J. 2005; 26(6): 974-7[PubMed]
  • 25. Yaghi C, Sharara AI, Rassam P, Moucari R, Honein K, BouJaoude J, et al. Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. World J Gastroenterol. 2006; 12(22): 3575-80[PubMed]
  • 26. Gulnaz A, Sayyed AH, Amin F, Khan A, Aslam MA, Shaikh RS, et al. Association of XRCC1, XRCC3, and XPD genetic polymorphism with an increased risk of hepatocellular carcinoma because of the hepatitis B and C virus. Eur J Gastroenterol Hepatol. 2013; 25(2): 166-79[DOI][PubMed]
  • 27. Butt AS, Hamid S, Wadalawala AA, Ghufran M, Javed AA, Farooq O, et al. Hepatocellular carcinoma in Native South Asian Pakistani population; trends, clinico-pathological characteristics & differences in viral marker negative & viral-hepatocellular carcinoma. BMC Res Notes. 2013; 6: 137[DOI][PubMed]
  • 28. Abbasi A, Bhutto AR, Butt N, Munir SM. Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. J Pak Med Assoc. 2012; 62(1): 33-6[PubMed]
  • 29. Abbasi A, Butt N, Bhutto AR, Gulzar K, Munir SM. Hepatocellular carcinoma: a clinicopathological study. J Coll Physicians Surg Pak. 2010; 20(8): 510-3[PubMed]
  • 30. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, et al. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol. 2009; 81(7): 1189-97[DOI][PubMed]
  • 31. Idrees M, Rafique S, Rehman I, Akbar H, Yousaf MZ, Butt S, et al. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. World J Gastroenterol. 2009; 15(40): 5080-5[PubMed]
  • 32. Ansari S, Memon MS, Devrajani BR. Frequency of hepatitis B and hepatitis C in patients with hepatocellular carcinoma at Hyderabad. JLUMHS. 2009; 8(2): 109
  • 33. Abbas Z, Siddiqui AU, Luck NH, Hassan M, Mirza R, Naqvi A, et al. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology. J Pak Med Assoc. 2008; 58(11): 602-7[PubMed]
  • 34. Hamza H, Akhtar S, Hamid S, Niaz S, Janjua N, Khan M. Role of hepatitis B and C virus infections in hepatocellular carcinoma: A case-control study in Karachi, Pakistan . XVIIth IEA World Congress of Epidemiology.
  • 35. Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll Abbottabad. 2003; 15(4): 1-4[PubMed]
  • 36. Sharieff S, Burney KA, Ahmad N, Salam A, Siddiqui T. Radiological features of hepatocellular carcinoma in Southern Pakistan. Trop Doct. 2001; 31(4): 224-5[PubMed]
  • 37. Mumtaz MS, Iqbal R, Umar M, Khar B, Mumtaz MO, Anwar F, et al. Sero-prevalence of hepatitis B and C viruses in hepatocellular carcinoma. J Rawal Med Coll. 2001; 5(2): 78-80
  • 38. Kausar S, Shafqat F, Shafi F, Khan AA. The association of hepatocellular carcinoma with hepatitis B and C viruses. Pak J Gastroenterol. 1998; 12: 1-2
  • 39. Butt AK, Khan AA, Alam A, Ahmad S, Shah SW, Shafqat F, et al. Hepatocellular carcinoma: analysis of 76 cases. J Pak Med Assoc. 1998; 48(7): 197-201[PubMed]
  • 40. Abdul Mujeeb S, Jamal Q, Khanani R, Iqbal N, Kaher S. Prevalence of hepatitis B surface antigen and HCV antibodies in hepatocellular carcinoma cases in Karachi, Pakistan. Trop Doct. 1997; 27(1): 45-6[PubMed]
  • 41. Tong CY, Khan R, Beeching NJ, Tariq WU, Hart CA, Ahmad N, et al. The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellular carcinoma. Epidemiol Infect. 1996; 117(2): 327-32[PubMed]
  • 42. Alkhayyat S, Fallatah HI, Akbar HO, Al Ahwal MS, Al Ghamdi WS. Causes and Stages of Hepatocellular Carcinoma at Patient Presentation at a Tertiary Medical Center in Western Saudi Arabia. J Cancer Res Ther. 2014; 5(14): 1303-10[DOI]
  • 43. Alsohaibani F, Porter G, Al-Ashgar H, Walsh M, Berry R, Molinari M, et al. Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. J Gastrointest Cancer. 2011; 42(4): 228-35[DOI][PubMed]
  • 44. Sanai FM, Sobki S, Bzeizi KI, Shaikh SA, Alswat K, Al-Hamoudi W, et al. Assessment of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma in Middle Eastern patients. Dig Dis Sci. 2010; 55(12): 3568-75[DOI][PubMed]
  • 45. Ayoola EA, Gadour MO. Hepatocellular carcinoma in Saudi Arabia: role of hepatitis B and C infection. J Gastroenterol Hepatol. 2004; 19(6): 665-9[DOI][PubMed]
  • 46. Bile K, Aden C, Norder H, Magnius L, Lindberg G, Nilsson L. Important role of hepatitis C virus infection as a cause of chronic liver disease in Somalia. Scand J Infect Dis. 1993; 25(5): 559-64[PubMed]
  • 47. Omer RE, Veer PV, Kadaru AMY, Kampman E, El Khidir IM, Fedail SS, et al. The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. Trans R Soc Trop Med Hyg. 2001; 95(5): 487-91[DOI]
  • 48. Said Y, Debbeche R, Ben Ali Z, Bouzid K, Trabelsi S, Bouzaidi S, et al. [Epidemiological, clinical and therapeutic features of hepatocellular carcinoma in cirrhotic patients]. Tunis Med. 2012; 90(6): 468-72[PubMed]
  • 49. Dogan E, Yalcin S, Koca D, Olmez A. Clinicopathological characteristics of hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev. 2012; 13(6): 2985-90[PubMed]
  • 50. Bassullu N, Turkmen I, Yaprak O, Dayangac M, Demirbas T, Guler N, et al. General evaluation of hepatectomy and hepatocellular carcinoma cases. turk j path. 2011; 27(3): 221[DOI]
  • 51. Akkiz H, Bayram S, Bekar A, Akgollu E, Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat. 2011; 18(7)-407[DOI][PubMed]
  • 52. Yildirim Y, Ozyilkan O, Bilezikci B, Akcali Z, Haberal M. Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival. Asian Pac J Cancer Prev. 2008; 9(2): 295-8[PubMed]
  • 53. Alacacioglu A, Somali I, Simsek I, Astarcioglu I, Ozkan M, Camci C, et al. Epidemiology and survival of hepatocellular carcinoma in Turkey: outcome of multicenter study. Jpn J Clin Oncol. 2008; 38(10): 683-8[DOI][PubMed]
  • 54. Ozer B, Serin E, Yilmaz U, Gumurdulu Y, Saygili OB, Kayaselcuk F, et al. Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey. Turk J Gastroenterol. 2003; 14(2): 85-90[PubMed]
  • 55. Uzunalimoglu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoglu S, et al. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci. 2001; 46(5): 1022-8[PubMed]
  • 56. Salem AK, Abdulrab A, Alfakeh Y, Aown A. Hepatocellular carcinoma in Yemeni patients: a single centre experience over an 8-year period. East Mediterr Health J. 2012; 18(7): 693-9[PubMed]
  • 57. Saeed NM, Bawazir AA, Al-Zuraiqi M, Al-Negri F, Yunus F. Why is hepatocellular carcinoma less attributable to viral hepatitis in Yemen? Asian Pac J Cancer Prev. 2012; 13(8): 3663-7[PubMed]
  • 58. Peto TJ, Mendy ME, Lowe Y, Webb EL, Whittle HC, Hall AJ. Efficacy and effectiveness of infant vaccination against chronic hepatitis B in the Gambia Hepatitis Intervention Study (1986-90) and in the nationwide immunisation program. BMC Infect Dis. 2014; 14: 7[DOI][PubMed]
  • 59. Al Ghamdi SS, Fallatah HI, Fetyani DM, Al-Mughales JA, Gelaidan AT. Long-term efficacy of the hepatitis B vaccine in a high-risk group. J Med Virol. 2013; 85(9): 1518-22[DOI][PubMed]
  • 60. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, et al. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer. 2006; 119(8): 1946-52[DOI][PubMed]
  • 61. Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2011; 20(11): 2362-8[DOI][PubMed]
  • 62. Alfaleh FZ, Nugrahini N, Maticic M, Tolmane I, Alzaabi M, Hajarizadeh B, et al. Strategies to manage hepatitis C virus infection disease burden - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 42-65[DOI][PubMed]
  • 63. Honarkar Z, Alavian SM, Samiee S, Saeedfar K, Zali MR. Occult hepatitis B among chronic liver disease patients. Saudi Med J. 2005; 26(4): 601-6[PubMed]
  • 64. Abdalhafeez AM, Khalid AE, Osama MK, Mohammed OH, Abdel Rahim MEH, Isam ME. Prevalence of occult hepatitis B virus (HBV) infections in haemodialysis patients in Khartoum State, Sudan from 2012 to 2014. J Med Lab Diagn. 2015; 6(4): 22-6[DOI]
  • 65. Rezaee-Zavareh MS, Einollahi B. Treatment of Occult Hepatitis C Virus Infection: Does It Need Special Attention? Hepatitis Monthly. 2014; 14(6)[DOI]
  • 66. Deuffic–Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012; 143(4): 974-85
  • 67. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8(2): 84-90
  • 68. Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, et al. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 2015; 22 Suppl 4: 21-41[DOI][PubMed]
  • 69. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV infection among thalassemia patients in eastern Mediterranean countries: a quantitative review of literature. IRCMJ. 2010; 2010(4): 365-76
  • 70. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014; 12: 145[DOI][PubMed]
  • 71. Persson EC, Quraishi SM, Welzel TM, Carreon JD, Gridley G, Graubard BI, et al. Risk of liver cancer among US male veterans with cirrhosis, 1969-1996. Br J Cancer. 2012; 107(1): 195-200[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments